Business Context and Reporting Period
Company: BioLineRx Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Business Overview: BioLineRx is a clinical-stage biopharmaceutical development company incorporated in Israel. The company focuses on identifying, in-licensing, and developing therapeutic candidates in oncology and immunology. It has no commercial products and generates no product revenue. Its strategy relies on advancing candidates through clinical trials and commercializing them via out-licensing or collaboration agreements.
Key Financial Metrics
All figures in thousands of U.S. dollars unless otherwise noted.
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $(11,489) | $(11,866) |
| Sales & Marketing Expenses | $(1,003) | $(1,589) |
| General & Administrative Expenses | $(3,704) | $(3,800) |
| Operating Loss | $(16,196) | $(17,255) |
| Net Loss | $(14,400) | $(11,076) |
| Cash and Cash Equivalents | $5,544 | $5,790 |
| Short-term Bank Deposits | $42,119 | $28,890 |
| Total Assets | $51,302 | $36,211 |
| Total Liabilities | $3,692 | $4,406 |
| Shareholders' Equity | $47,610 | $31,805 |
| Accumulated Deficit | ~$(159.4 million) | N/A |
Liquidity: As of December 31, 2015, the company held approximately $47.7 million in cash, cash equivalents, and short-term bank deposits. Management believes these resources are sufficient to fund operations into 2018.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased to $14.4 million in 2015 from $11.1 million in 2014. This was primarily driven by a decrease in non-operating income (fair value adjustments on warrant liabilities) and a decrease in financial income (due to the change in functional currency from NIS to USD in 2015, eliminating significant exchange rate gains recorded in 2014).
- Operating Expenses: Operating loss improved slightly to $16.2 million from $17.3 million. R&D expenses decreased by 3.4% due to reduced spending on BL-7010 and other projects, partially offset by increased spending on BL-8040. Sales and marketing expenses decreased by 37.5% due to lower professional fees related to business development activities.
- Balance Sheet: Total assets increased significantly to $51.3 million from $36.2 million, driven by an increase in short-term bank deposits. Total liabilities decreased to $3.7 million from $4.4 million.
- Currency Change: Effective January 1, 2015, the company changed its functional and reporting currency from the New Israeli Shekel (NIS) to the U.S. Dollar (USD).
Guidance, Outlook, and Risks
Outlook and Guidance: The company expects to continue incurring significant operating losses as it advances its therapeutic candidates. It anticipates that existing cash and investment balances will be sufficient to meet requirements into 2018. Future capital requirements will depend on the progress of clinical trials, regulatory approvals, and the success of out-licensing arrangements.
Key Pipeline Updates:
- BL-8040 (Oncology/Hematology): Phase 2 trial for Acute Myeloid Leukemia (AML) is ongoing; top-line results expected in Q1 2016. Phase 2 trial for stem cell mobilization expected to commence in Q1 2016. New Phase 2b consolidation trial for AML initiated in Germany.
- BL-7010 (Celiac/Gluten Sensitivity): Phase 1/2 trial completed. Classified as a Class IIb medical device in the EU. Exploring food supplement pathway for the U.S. market.
- BL-5010 (Skin Lesions): Out-licensed to Omega Pharma for OTC indications in Europe/Australia. Commercial launch expected in 2016.
Material Risks:
- Regulatory Approval: No products are approved; failure to obtain FDA or foreign regulatory approval would prevent commercialization.
- Clinical Trial Uncertainty: Clinical trials are expensive and have uncertain outcomes; negative results could halt development.
- Liquidity: The company has a history of losses and may require additional financing. If funds are not available, it may need to delay or reduce development programs.
- Dependence on Partners: Reliance on out-licensing partners (e.g., Omega Pharma, Novartis, Bellerophon) for late-stage development and commercialization.
- Geopolitical Risk: Operations are based in Israel; political or military instability in the region could adversely affect business.
- Intellectual Property: Reliance on in-licensed technology; termination of licenses or patent challenges could impact the pipeline.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $47.7 million cash balance against projected burn rates for 2016-2018, considering the high cost of Phase 2/3 trials.
- BL-8040 Trial Results: Monitor the top-line results of the AML Phase 2 trial expected in Q1 2016, as this is a critical value driver.
- Partnership Milestones: Track the commercial launch of BL-5010 by Omega Pharma and the status of the Novartis collaboration for potential milestone payments.
- Regulatory Status: Confirm the classification of BL-7010 as a medical device in the EU and the progress of the food supplement pathway in the U.S.
- Government Grants: Review the implications of the Israeli R&D Amendment (effective Jan 1, 2016) on future government funding and royalty obligations to the Office of the Chief Scientist.
- Warrant Liabilities: Assess the impact of fair value adjustments on warrant liabilities on future non-operating income/expense volatility.